Monopar Therapeutics Inc. Profile Avatar - Palmy Investing

Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet…

Biotechnology
US, Wilmette [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Monopar Therapeutics Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Monopar Therapeutics Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Monopar Therapeutics Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of MNPR's Analysis
CIK: 1645469 CUSIP: 61023L108 ISIN: US61023L1089 LEI: - UEI: -
Secondary Listings
MNPR has no secondary listings inside our databases.